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Objective: The aim of this study was to evaluate right and left ventricular functions in patients with pulmonary
arterial hypertension after living-donor lobar lung transplantation compared with those without hypertension.
Methods: Thirty-three recipients of living-donor lobar lung transplantation were divided into two groups: those
with pulmonary arterial hypertension (PAH group; n ¼ 12) and those without (non-PAH group; n ¼ 21). Their
systolic pulmonary artery pressure was 93.1 6.7 mm Hg versus 31.4 2.9 mm Hg, respectively. Right and left
ventricular ejection fractions, systolic pulmonary artery pressure, and cardiac index were serially measured by
radionuclide ventriculography and right heart catheterization, respectively.
Results: Pretransplant right and left ventricular ejection fractions were lower in the PAH group (29.8% 7.0%,
49.9%  6.6%) than in the non-PAH group (49.7%  3.3%, 65.2%  1.9%) (P ¼ .010, .068). Two months
after living-donor lobar lung transplantation, right ventricular ejection fraction and systolic pulmonary artery
pressure in the PAH group (57.3%  5.1%, 25.7  1.8 mm Hg) improved dramatically, equal to those in the
non-PAH group. In contrast, left ventricular ejection fraction and cardiac index in the PAH group (50.9% 
3.7%, 2.66  0.12 L $ min1 $ m2) were still significantly lower than in the non-PAH group (65.4% 
2.8%, 3.13 0.15 L $min1 $m2) (P¼ .0038, .037). At 6 to 12 months, the PAH group demonstrated a signif-
icant rise in left ventricular ejection fraction and cardiac index that reached similar values in the non-PAH group
measured at 2 months. These values were stable for up to 3 years.
Conclusions: Right ventricular function recovered early after living-donor lobar lung transplantation in the PAH
group. In contrast, recovery of left ventricular function required 6 to 12 months. Improved cardiac function was
sustained for up to 3 years, suggesting long-term durability of cardiac function recovery after living-donor lobar
lung transplantation.Lung transplantation has been performed as an effective
treatment for various kinds of pulmonary disease. Living-
donor lobar lung transplantation (LDLLT) was developed
at Stanford University and has been established at the Univer-
sity of Southern California as a safe and reproducible proce-
dure to deal with the shortage of cadaveric donors.1 LDLLT
has been used in patients with a variety of end-stage pulmo-
nary diseases, including pulmonary arterial hypertension
(PAH), who are too ill to wait for cadaveric lung transplanta-
tion.2 PAH is defined as a group of diseases characterized by
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doi:10.1016/j.jtcvs.2009.02.038222 The Journal of Thoracic and Cardiovascular Sua progressive increase in pulmonary vascular resistance. Con-
sequently, right ventricular enlargement with hypertrophy
occurs, and the enlarged right ventricle, by compressing the
left ventricle, limits its volume and results in severe pump
dysfunction. Three classes of medications have now shown
efficacy in the treatment of PAH: prostanoids,3,4 endothelin
receptor antagonists,5 and phosphodiesterase-5 inhibitors.6
When all these medical treatments fail, lung transplantation
remains the treatment of last resort.
From January 2000, we began to apply LDLLT to both
pediatric7 and adult8 patients with PAH. Recently, we9 re-
ported excellent clinical outcomes of LDLLT for 11 patients
with PAH for whom mortality was likely to be high without
lung transplantation. Although a limited amount of lung tis-
sue was implanted, pulmonary artery pressure (PAP) nor-
malized soon after LDLLT.
It has been clearly shown that a significant improvement
in right ventricular function occurs after single or double
lung transplantation in patients with PAH.10-13 In contrast,
left ventricular recovery has not been well studied. Further-
more, little is known about right and left ventricular func-
tions after LDLLT in which a limited amount of lungrgery c July 2009
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CI ¼ cardiac index
FVC ¼ forced vital capacity
LDLLT ¼ living-donor lobar lung transplantation
LVEF ¼ left ventricular ejection fraction
PAH ¼ pulmonary arterial hypertension
PAP ¼ pulmonary artery pressure
RVEF ¼ right ventricular ejection fraction
sPAP ¼ systolic pulmonary artery pressure
tissue is implanted. For this purpose, we serially measured
right and left ventricular functions of patients with PAH re-
ceiving LDLLT and compared them to those of patients
without PAH.
PATIENTS AND METHODS
Recipient and Donor Selection
All recipients fulfilled the criteria for conventional bilateral lung trans-
plantation. We have accepted only critically ill patients as candidates for
LDLLT and only relatives within the second degree or a spouse as living
donors. Each case was carefully reviewed by the Lung Transplant Evalua-
tion Committee at Okayama University Graduate School of Medicine, Den-
tistry and Pharmaceutical Sciences. Regarding size matching, we14 have
previously proposed a formula to estimate the forced vital capacity (FVC)
of the graft on the basis of the donor’s measured FVC and the number of
pulmonary segments implanted.We accepted the size disparity when the to-
tal FVC of the 2 grafts was more than 45% of the predicted FVC of the re-
cipient for non-PAH and when it was more than 50% for PAH.
Surgical Procedures
The surgical aspects of LDLLT have been described previously.14 The
right and left lower lobes were removed from 2 healthy donors. These 2
lobes were then implanted in the recipient under cardiopulmonary bypass
as whole right and left lungs. Just before reperfusion, 500 mg to 1 g of meth-
ylprednisolone was administered intravenously, and nitric oxide inhalation
was initiated at 20 ppm. To maintain patients’ nutritional status and for peri-
operative drug delivery, we inserted a nasal feeding tube to the proximal
jejunum at the conclusion of the operation.
Postoperative Management of the Recipient
The patient was kept intubated for at least 3 days to maintain optimal ex-
pansion of the lobes. Weaning from a ventilator was intentionally slow, and
tracheostomy was performed when patients showed any signs of sputum re-
tention. Postoperative immunosuppression consisted of triple-drug therapy
under a previously described protocol. Three months after LDLLT, patients
were allowed to return to their home town. Routine full postoperative as-
sessment was performed at 6 months, 12 months, and then annually.
Assessment of Cardiac Function
We measured right and left ventricular ejection fractions (RVEF and
LVEF) by radionuclide ventriculography, which was performed by a bolus
injection of technetium Tc 99m. For determination of RVEF, a gated first-
pass study was performed at rest. LVEF was measured by the equilibrium
method. Radionuclide ventriculography was performed before transplanta-
tion, at 2 months, 6 months, and then annually after transplantation for PAH
patients. It was performed before transplantation, at 2 months, and 6 months
after transplantation for non-PAH patients.The Journal of Thoracic and CPulmonary hemodynamics was measured by a right heart catheter exam-
ination using a Swan-Ganz catheter (Edwards LifeSciences, Irvine, Calif).
Cardiac output was calculated by the Fick equation, thermodilution tech-
nique, or both. Right heart catheterization was performed before transplan-
tation, at 2 months, 1 year, and 3 years after transplantation for PAH
patients. It was performed before transplantation and at 2 months after trans-
plantation for non-PAH patients. All data were prospectively collected.
Statistical Analysis
The differences of significance among categorized groups were com-
pared by unpaired Student t tests or Fisher’s exact tests. Statistical analyses
were conducted by StatView 5.0 Program for Windows (SAS Institute Inc,
Cary, NC). All statistical tests were 2-sided.
RESULTS
Patient Characteristics
We performed LDLLT in 41 patients between October
1998 and September 2006 at our institution (Okayama).
Among the 41 recipients, 39 (95.1%) survived longer than
6 months. Early death occurred in 2 patients (idiopathic
interstitial pneumonia and bronchiolitis obliterans after
bone marrow transplantation) owing to acute rejection and
Aspergillus infection, respectively. To simplify the study,
we excluded 6 patients from further analysis because of sig-
nificant secondary pulmonary hypertension (systolic PAP
[sPAP]> 65 mm Hg) in 3 patients, small graft size (less
than 50% of predicted FVC) in 2 patients, and single lobe
transplantation in 1 patient.
Therefore, 33 patients were enrolled in this study. These
patients were divided into two groups, the PAH group (n ¼
12) and the non-PAH group (n ¼ 21). The details of patient
characteristics are shown in Table 1. Patients in the PAH
group were significantly younger than those in the non-
PAH group (24.1  3.1 years vs 37.2  2.8 years;
P ¼ .0062). The estimated graft FVC was similar between
the two groups (71.2% 4.1% vs 65.3% 2.6%;P¼ .21).
ThePAHgroup includedpatientswith idiopathicPAH, pul-
monary veno-occlusive disease, and pulmonary capillary he-
magiomatosis. All 12 patients in the PAH group were
receiving high-dose intravenous epoprostenol (94  14 ng $
kg1 $ min1) for 707  163 days at the time of LDLLT.
One patientwas receiving the oral dual endothelin receptor an-
tagonist bosentan, which became available in June 2005.
Eleven patients required inotropic support. The non-PAH
group included patientswith idiopathic interstitial pneumonia,
bronchiolitis obliterans, lymphangioleiomyomatosis, bronchi-
ectasis, cystic fibrosis, and chronic obstructive lung disease.
Postoperative Course
Transient lung edema associated with left ventricular fail-
ure occurred in 3 (25%) recipients in the PAH group, but
was not seen in any recipients in the non-PAH group early
after LDLLT. One patient in the non-PAH group required
mechanical ventilation for 121 days owing to bilateral
phrenic nerve palsy. Excluding this patient, the duration ofardiovascular Surgery c Volume 138, Number 1 223
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significantly longer in the PAH group than in the non-
PAH group (16.6  3.8 days vs 7.6  1.5 days; P< .001).
As of August 2007, there were 3 late deaths and 30 (91%)
of 33 recipients were alive with a mean follow-up period of
4.2 years. One patient with idiopathic PAH died of chronic
rejection at 65 months, 1 patient with bronchiolitis obliterans
died of encephalitis at 11 months, and 1 patient with idio-
pathic interstitial pneumonia died of chronic rejection at
31 months after LDLLT.
Comparison of Cardiac Function Between the PAH
and Non-PAH Groups
Serial comparisons of RVEF, LVEF, sPAP (mm Hg), and
cardiac index (CI) (L $min1 $m2) between the PAH group
and the non-PAH group are shown in Table 2. Some of the
planned examinations could not be performed because some
patients were too sick.
RVEF was significantly lower in the PAH group than in
the non-PAH group before transplantation (29.8%  7.0%
vs 49.7%  3.3%; P ¼ .010). At 2 months after LDLLT,
RVEF in the PAH group improved dramatically and equaled
that in the non-PAH group (57.3%  5.1% vs 58.3% 
2.8%; P ¼ .86). Interestingly, RVEF became significantly
higher in the PAH group than in the non-PAH group at
6 months (65.1%  2.4% vs 57.2%  2.0%; P ¼ .020).
LVEF tended to be lower in the PAH group than in the
non-PAH group before transplantation (49.9%  6.6% vs
65.2% 1.9%;P¼ .068). At 2months, contrary to the early
RVEF recovery, LVEF in the PAH group did not improve
and was significantly lower than in the non-PAH group
(50.9%  3.7% vs 65.4%  2.8%; P ¼ .0038). At 6
months, the recipients in the PAH group demonstrated a sig-
nificant rise in LVEF to values similar to those in the non-
PAH group (64.1%  3.2% vs 63.0%  2.4%; P ¼ .78).
TABLE 1. Patient characteristics
Variables
PAH group
(n ¼ 12)
Non-PAH group
(n ¼ 21) P value
Female/male 9/3 18/3 .64
Age (y) 24.1  3.1 37.2  2.8 .0062
Graft size (%) 71.2  4.1 65.3  2.6 .21
Diseases
IPAH 9 0
PVOD 2 0
PCH 1 0
IIP 0 8
BO 0 5
LAM 0 3
BE 0 3
CF 0 1
COPD 0 1
IPAH, Idiopathic pulmonary arterial hypertension; PVOD, pulmononary veno-occlu-
sive disease; PCH, pulmonary capillary hemangiomatosis; IIP, idiopathic interstitial
pneumonitis; BO, bronchiolitis obliterans; LAM, lymphangioleiomyomatosis; BE,
bronchiectasis; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease.224 The Journal of Thoracic and Cardiovascular SursPAP was significantly higher in the PAH group than in
the non-PAH group before transplantation (93.1  6.7 mm
Hg vs 31.4  2.9 mm Hg; P< .0001). Both groups showed
a significant reduction in sPAP to normal levels at 2 months
(25.7  1.8 mm Hg vs 22.4  1.2 mm Hg; P ¼ .13).
CI was significantly lower in the PAH group than in the
non-PAH group before transplantation (2.03  0.12 L $
min1 $ m2 vs 3.49  0.24 L $ min1 $ m2; P< .0001).
At 2 months, CI in the PAH group improved significantly
but was still significantly lower than that in the non-PAH
group (2.66  0.12 L $ min1 $ m2 vs 3.13  0.15 L $
min1 $ m2; P ¼ .037). CI in the PAH group further im-
proved to 3.23  0.20 L $ min1 $ m2 at 1 year.
The time course changes of RVEF, LVEF, sPAP, and CI
are shown in Figure 1. RVEF and sPAP in the PAH group
recovered to the levels in the non-PAH group within 2
months after LDLLT. In contrast, recovery of LVEF and
CI required 6 to 12 months. In the PAH group, RVEFs at
1, 2, and 3 years were 64.0%  3.0%, 66.2%  3.1%,
and 66.6% 3.6%, respectively. LVEFs at 1, 2, and 3 years
were 61.4% 2.2%, 66.0% 3.5%, and 70.9% 3.7%,
respectively. sPAPs at 1 and 3 years were 26.1 2.7 mmHg
and 22.4  1.4 mm Hg. CIs at 1 and 3 years were 3.23 
0.20 L $ min1 $ m2 and 2.98  0.17 L $ min1 $ m2, re-
spectively. These results indicated that the improved cardiac
function and pulmonary hemodynamics were well main-
tained for up to 3 years in the PAH group.
DISCUSSION
Isolated lung transplantation, either single or bilateral, has
been successfully performed in patients with end-stage
TABLE 2. Comparison of cardiac function and pulmonary
hemodynamics between PAH and non-PAH groups
Variables
PAH group
(n ¼ 12)
Non-PAH group
(n ¼ 21)
P
value
Before LDLLT
RVEF (%) 29.8  7.0 (n ¼ 6) 49.7  3.3 (n ¼ 11) .010
LVEF (%) 49.9  6.6 (n ¼ 6) 65.2  1.9 (n ¼ 11) .068
sPAP (mm Hg) 93.1  6.7 (n ¼ 12) 31.4  2.9 (n ¼ 12) <.0001
CI (L $ min1 $
m2)
2.03  0.12 (n ¼ 12) 3.49  0.24 (n ¼ 12) <.0001
Two months
after LDLLT
RVEF (%) 57.3  5.1 (n ¼ 11) 58.3  2.8 (n ¼ 14) .86
LVEF (%) 50.9  3.7 (n ¼ 11) 65.4  2.8 (n ¼ 14) .0038
sPAP (mm Hg) 25.7 1.8 (n ¼ 12) 22.4  1.2 (n ¼ 19) .13
CI (L $ min1 $
m2)
2.66  0.12 (n ¼ 12) 3.13  0.15 (n ¼ 19) .037
Six months
after LDLLT
RVEF (%) 65.1  2.4 (n ¼ 11) 57.2  2.0 (n ¼ 19) .020
LVEF (%) 64.1  3.2 (n ¼ 11) 63.0  2.4 (n ¼ 19) .78
PAH, Pulmonary arterial hypertension; LDLLT, living-donor lobar lung transplanta-
tion; RVEF, right ventricular ejection fraction; LVEF, left ventricular ejection fraction;
sPAP, systolic pulmonary arterial pressure; CI, cardiac index.gery c July 2009
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FIGURE 1. The time course changes of RVEF (A), LVEF (B), sPAP (C), and CI (D) after LDLLT. RVEF and sPAP became similar between the PAH group
and non-PAH groups at 2 months. In contrast, LVEF and CI were significantly lower in the PAH group than in the non-PAH group at 2 months. At 6 to 12
months, the PAH group showed normal RVEF, LVEF, sPAP and CI. These values continued to be normal for up to 3 years. RVEF, Right ventricular ejection
fraction; LVEF, left ventricular ejection fraction; sPAP, systemic pulmonary artery pressure; CI, cardiac index; PAH, pulmonary arterial hypertension.T
XPAH.10-13 Compared with heart–lung transplantation, lung
transplantation has the advantage of sparing the recipients’
own heart, an important factor considering the scarcity of
the available donor pool. However, the recipient’s heart
has been working against PAH for a certain period of time
before transplantation, leading to right ventricular dilatation
and left ventricular deformation by septal flattening toward
its cavity. A number of studies have shown that right ven-
tricular function and PAP improve dramatically soon after
single and bilateral isolated lung transplantation.10-13 In
contrast, changes in left ventricular function have not been
well studied.
We began to apply LDLLT to both pediatric7 and adult8
patients with PAH. Although a limited amount of lung tissue
was implanted, PAP became nearly normal at 2 months, val-
idating the functional capacity of 2 adult lobes to handle the
cardiac output of a recipient with PAH. However, we ob-
served frequent transient lung edema associatedwith left ven-The Journal of Thoracic and Ctricular dysfunction in this group of recipients. The present
study was conducted to evaluate time course changes in right
and left ventricular functions and pulmonary hemodynamics
in patients with PAH receiving LDLLT. To obtain objective
data, we used radionuclide ventriculography and right heart
catheterization. Echocardiography was not chosen because
dramatic geometric changes caused by LDLLTmade it diffi-
cult to evaluate right and left ventricular functions.
The present study clearly demonstrated rapid recovery of
right ventricular function and PAP within 2 months after
LDLLT in the PAH group. The better RVEF in the PAH
group compared with the non-PAH group at 6 months might
be related to the fact that the right ventricle had been
‘‘trained’’ by high afterload owing to severe PAH. This re-
sult also suggests that the right ventricle is not irreversibly
damaged in pump function by enlargement and hypertrophy
under high afterload conditions. Previous studies on patients
receiving cadaveric lung transplants also demonstrated thatardiovascular Surgery c Volume 138, Number 1 225
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cardiac geometry regardless of the pre-existing right ventric-
ular enlargement and tricuspid insufficiency.10-13
Contrary to the early recovery of right ventricular func-
tion, the impaired left ventricular function persisted at 2
months despite findings that left ventricular geometry was
restored earlier after reversal of PAH. This finding suggests
that factors other than ventricular geometry may play a role.
Using Doppler echocardiography, Xie and his colleagues15
also reported that the left ventricular geometry became
more circular; however, impaired early filling persisted after
single lung transplantation. Chronic preload reduction may
adversely affect the left ventricular compliance and muscle
stiffness. Our patients with PAHwere receiving full pharma-
cologic treatment including high-dose intravenous epopros-
tenol. It therefore can be anticipated that these patients were
in a much more debilitated state for a longer period than pa-
tients referred for lung transplantation 10 years ago.
Three of the first 6 patients with PAH had transient lung
edema associated with left ventricular dysfunction 5, 14,
and 28 days after LDLLT, respectively. Lung edema oc-
curred suddenly, and these 3 patients did not show any
sign of lung edema before these episodes. Clinical findings
demonstrated by echocardiography helped establish the di-
agnosis of left ventricular dysfunction. This complication
has also been reported after conventional bilateral lung
transplantation.16 The withdrawal of mechanical ventilation
along with the subsequent increase of venous return and car-
diac preload, associated with the augmented work of breath-
ing, may be the cause of the edema. Although postoperative
days of left ventricular dysfunction varied, we believe that
the pathophysiology of this complication in these 3 patients
was similar. All 3 patients responded to therapy including
steroid pulse, inotropic drugs, afterload reduction with vaso-
dilators, and nitric oxide inhalation. The last 6 patients with
PAH were supported by a ventilator for at least a week and
weaned very slowly along with elective tracheostomy. A left
atrial line was placed through the left appendage at the time
of transplantation, and left atrial pressure was carefully mon-
itored. Inotropes, diuretics, and nitric oxide inhalation were
used longer. As a result, none of the last 6 patients with PAH
had lung edema. Meticulous postoperative management is
mandatory because mild left ventricular dysfunction may
easily result in lung edema after LDLLT, in which a limited
amount of lung tissue is transplanted.
At 6 months to 1 year, the recipients in the PAH group
demonstrated a significant rise in LVEF and CI to the similar
values in the non-PAHgroupmeasured at 2months, and these
values were stable for up to 3 years. These findings suggest226 The Journal of Thoracic and Cardiovascular Suthat left ventricular physiologic function can also recover
completely and, once it has recovered, it lasts long term.
In conclusion, right ventricular function recovered early
after LDLLT for PAH; however, recovery of left ventricular
function required 6 to 12 months. The high incidence of lung
edema early after LDLLT may be partially related to the dis-
sociation between physiologic and geometric recovery in
left ventricular function. Improved cardiac function was sus-
tained for up to 3 years, suggesting long-term durability of
cardiac function recovery. Excellent prognosis and complete
recovery of right and left ventricular functions support the
option of LDLLT for patients with severe PAH.
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